MeSH term
Frequency | Condition_Probility | Adult | 236 | 0.0 |
Humans | 967 | 0.0 |
Male | 255 | 0.0 |
Middle Aged | 183 | 0.0 |
Reference Values | 13 | 0.0 |
Risk Factors | 5 | 0.0 |
Weight Loss | 2 | 1.0 |
Clinical Trials | 8 | 0.0 |
Cytokines/*immunology | 5 | 5.0 |
Dendritic Cells/immunology | 2 | 1.0 |
T-Lymphocytes, Cytotoxic/immunology | 11 | 2.0 |
Acute Disease | 13 | 0.0 |
Aged | 118 | 0.0 |
Aged, 80 and over | 27 | 0.0 |
Antigens, CD56/analysis | 4 | 6.0 |
Asthma/*immunology | 6 | 7.0 |
RNA, Messenger/analysis | 16 | 0.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis | 3 | 6.0 |
Th2 Cells/*immunology | 3 | 2.0 |
English Abstract | 95 | 0.0 |
Lymphocytes | 2 | 1.0 |
Macrophages | 2 | 2.0 |
Cell Adhesion/drug effects | 2 | 0.0 |
Cells, Cultured | 163 | 0.0 |
Cytotoxicity Tests, Immunologic | 8 | 1.0 |
Drug Synergism | 23 | 1.0 |
Female | 256 | 0.0 |
Interleukin-2/*pharmacology | 67 | 26.0 |
Research Support, U.S. Gov't, P.H.S. | 176 | 0.0 |
Antigens, CD/blood | 3 | 1.0 |
Antigens, Differentiation/*blood | 2 | 11.0 |
CD4-CD8 Ratio | 9 | 1.0 |
Cytokines/blood | 7 | 3.0 |
Ferritin/blood | 2 | 1.0 |
*Immunoconjugates | 4 | 1.0 |
Lymphocytes/*immunology | 19 | 4.0 |
*Renal Dialysis | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 582 | 0.0 |
Time Factors | 43 | 0.0 |
Transferrin/metabolism | 4 | 2.0 |
*Aging | 2 | 1.0 |
Flow Cytometry | 50 | 0.0 |
Lymphocyte Count | 7 | 1.0 |
Animals | 223 | 0.0 |
CA-15-3 Antigen/*immunology | 2 | 3.0 |
Immunity, Cellular | 23 | 3.0 |
Interferon Type II/biosynthesis | 24 | 5.0 |
Interleukin-2/*secretion | 5 | 33.0 |
Mice | 144 | 0.0 |
Mice, SCID | 4 | 0.0 |
Histocompatibility Antigens/analysis | 3 | 4.0 |
Kinetics | 47 | 0.0 |
Receptor Aggregation | 2 | 2.0 |
Receptors, Immunologic/*analysis | 5 | 9.0 |
Signal Transduction | 15 | 0.0 |
Coculture Techniques | 5 | 0.0 |
Cytogenetic Analysis | 2 | 1.0 |
Interleukin-2/pharmacology | 88 | 15.0 |
Tumor Cells, Cultured | 77 | 0.0 |
Carcinoma, Renal Cell/*immunology | 3 | 16.0 |
Kidney Neoplasms/*immunology | 3 | 11.0 |
Membrane Glycoproteins/immunology | 3 | 1.0 |
CD4 Lymphocyte Count | 4 | 0.0 |
CD8-Positive T-Lymphocytes/immunology | 4 | 0.0 |
Interferon Type II/metabolism | 6 | 2.0 |
Interleukin-10/metabolism | 3 | 4.0 |
Interleukin-2/metabolism | 17 | 11.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 35 | 0.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Adolescent | 56 | 0.0 |
Alleles | 4 | 0.0 |
Bone Marrow Transplantation/*immunology | 5 | 4.0 |
Cell Culture Techniques/methods | 3 | 1.0 |
Clone Cells | 26 | 2.0 |
Immunophenotyping | 25 | 0.0 |
Killer Cells, Natural/*immunology | 21 | 4.0 |
T-Lymphocytes/immunology | 36 | 2.0 |
Tissue Donors | 2 | 0.0 |
Carcinoma, Renal Cell/*drug therapy/immunology | 2 | 40.0 |
Cytokines/*pharmacology/therapeutic use | 2 | 50.0 |
Dose-Response Relationship, Drug | 31 | 0.0 |
Interferon-alpha/pharmacology | 3 | 3.0 |
Kidney Neoplasms/*drug therapy/immunology | 2 | 28.0 |
Multicenter Studies | 4 | 3.0 |
Randomized Controlled Trials | 3 | 0.0 |
Interleukin-2/pharmacology/*therapeutic use | 3 | 42.0 |
*Killer Cells, Lymphokine-Activated | 4 | 57.0 |
Treatment Outcome | 15 | 0.0 |
Biological Markers | 4 | 0.0 |
Biopsy | 8 | 0.0 |
Immunohistochemistry | 13 | 0.0 |
Base Sequence | 42 | 0.0 |
Child | 46 | 0.0 |
DNA Primers | 6 | 0.0 |
Antigens, CD4/analysis | 12 | 2.0 |
Antigens, CD8/analysis | 7 | 2.0 |
Cell Survival | 5 | 0.0 |
Comparative Study | 98 | 0.0 |
Cytokines/analysis | 2 | 2.0 |
Ionomycin | 5 | 21.0 |
Leukocytes, Mononuclear/drug effects/immunology | 4 | 8.0 |
Synovial Fluid/immunology | 2 | 5.0 |
T-Lymphocytes/drug effects/*immunology | 7 | 4.0 |
Th1 Cells/immunology | 3 | 1.0 |
Cytokines/*blood | 8 | 2.0 |
Interleukins/blood | 3 | 7.0 |
Tumor Necrosis Factor-alpha/analysis | 6 | 1.0 |
Arthritis, Rheumatoid/*immunology/pathology | 2 | 6.0 |
Gastroscopy | 2 | 4.0 |
Gene Expression | 18 | 0.0 |
RNA, Messenger/genetics | 18 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Cell Count | 6 | 0.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Cell Division | 51 | 1.0 |
Interleukin-10/biosynthesis | 5 | 4.0 |
Interleukin-2/biosynthesis | 53 | 12.0 |
Lymphocyte Activation | 146 | 4.0 |
Tumor Necrosis Factor-alpha/metabolism | 5 | 0.0 |
Antibodies, Monoclonal/therapeutic use | 4 | 2.0 |
Immunosuppressive Agents/*therapeutic use | 4 | 3.0 |
Interleukin-2/*immunology | 32 | 48.0 |
Kidney Transplantation/immunology | 3 | 5.0 |
Aging/*immunology | 8 | 6.0 |
Ionomycin/pharmacology | 8 | 3.0 |
Lymphocyte Activation/*immunology | 11 | 2.0 |
Phosphorylation | 12 | 0.0 |
Phytohemagglutinins/pharmacology | 64 | 12.0 |
Receptors, Antigen, T-Cell/immunology | 12 | 6.0 |
Tetradecanoylphorbol Acetate/pharmacology | 40 | 2.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 12 | 2.0 |
Tyrosine/metabolism | 4 | 0.0 |
Killer Cells/*immunology | 9 | 26.0 |
Lymphocyte Activation/immunology | 11 | 2.0 |
Receptors, Immunologic/*immunology/metabolism | 2 | 15.0 |
Signal Transduction/immunology | 3 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 23 | 4.0 |
United States | 2 | 0.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
DNA/metabolism | 4 | 0.0 |
Growth Substances/*pharmacology | 4 | 1.0 |
Molecular Sequence Data | 55 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
HIV Infections/*drug therapy | 2 | 0.0 |
Interleukin-2/adverse effects/*therapeutic use | 9 | 50.0 |
Amino Acid Sequence | 35 | 0.0 |
Antigens, CD4/*immunology | 4 | 1.0 |
Baculoviridae/genetics | 2 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 26 | 0.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
*Nuclear Warfare | 2 | 15.0 |
Antigens, CD3/analysis | 5 | 2.0 |
Cell Division/drug effects | 44 | 1.0 |
Genotype | 6 | 0.0 |
Stem Cell Factor/pharmacology | 2 | 1.0 |
Case-Control Studies | 12 | 0.0 |
Cell Adhesion Molecules/analysis | 2 | 1.0 |
HLA-DR Antigens/analysis | 6 | 0.0 |
Hydrogen-Ion Concentration | 6 | 0.0 |
Receptors, Interleukin-2/analysis | 15 | 5.0 |
DNA Primers/chemistry | 2 | 0.0 |
*Gene Transfer Techniques | 2 | 0.0 |
In Vitro | 112 | 1.0 |
Mice, Inbred C57BL | 9 | 0.0 |
Polymerase Chain Reaction | 18 | 0.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 11 | 5.0 |
CD4-Positive T-Lymphocytes/immunology | 6 | 0.0 |
Cell Death | 3 | 0.0 |
*Immunotherapy | 18 | 11.0 |
Transfection | 24 | 0.0 |
Adenoviridae/*genetics | 2 | 0.0 |
Antibodies, Monoclonal | 37 | 1.0 |
Lymphocyte Depletion | 8 | 4.0 |
Models, Molecular | 4 | 0.0 |
Protein Binding | 5 | 0.0 |
Protein Conformation | 7 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Structure-Activity Relationship | 9 | 0.0 |
Interferon-gamma, Recombinant/pharmacology | 4 | 2.0 |
*Signal Transduction | 2 | 0.0 |
Cell Line | 106 | 0.0 |
Clathrin/*metabolism | 2 | 5.0 |
Hela Cells | 6 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
Receptors, Interleukin-2/*metabolism | 10 | 13.0 |
Estradiol/blood | 2 | 0.0 |
Interleukin-2/*blood | 3 | 13.0 |
Lymphocytes/metabolism | 3 | 1.0 |
Antibodies, Monoclonal/*therapeutic use | 7 | 2.0 |
Interleukin-4/metabolism | 4 | 4.0 |
Statistics, Nonparametric | 5 | 0.0 |
T-Lymphocytes/drug effects/metabolism | 3 | 8.0 |
Th1 Cells/metabolism | 2 | 7.0 |
Tumor Necrosis Factor-alpha/*immunology | 2 | 1.0 |
Cell Survival/drug effects | 8 | 0.0 |
Proteins/metabolism | 3 | 0.0 |
Cohort Studies | 3 | 0.0 |
Cytokines/*genetics/metabolism | 3 | 18.0 |
DNA/genetics | 6 | 0.0 |
Interferon Type II/genetics | 9 | 11.0 |
Interleukin-2/genetics | 14 | 16.0 |
Interleukin-6/genetics | 2 | 2.0 |
Multivariate Analysis | 4 | 0.0 |
Random Allocation | 3 | 0.0 |
T-Lymphocytes/cytology/*metabolism | 3 | 10.0 |
Tumor Necrosis Factor-alpha/genetics | 4 | 1.0 |
Antibody Specificity | 5 | 0.0 |
Follow-Up Studies | 5 | 0.0 |
Interferon Type II/*biosynthesis | 9 | 5.0 |
Interleukin-2/*biosynthesis | 44 | 30.0 |
Pilot Projects | 6 | 0.0 |
Prospective Studies | 6 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Genetic Vectors | 8 | 0.0 |
Blotting, Western | 5 | 0.0 |
Antibodies/therapeutic use | 2 | 11.0 |
Cytokines/*therapeutic use | 3 | 16.0 |
Disease Models, Animal | 8 | 0.0 |
Interleukin-2/therapeutic use | 8 | 20.0 |
Recombinant Fusion Proteins/therapeutic use | 3 | 12.0 |
Survival Analysis | 3 | 0.0 |
Tumor Necrosis Factor-alpha/therapeutic use | 2 | 14.0 |
Autoimmune Diseases/*immunology | 4 | 2.0 |
Cytokines/*analysis | 7 | 8.0 |
Interferon Type II/analysis | 5 | 5.0 |
Interleukin-10/analysis | 2 | 5.0 |
Interleukin-2/analysis | 4 | 9.0 |
Interleukin-4/analysis | 3 | 7.0 |
Th1 Cells/*immunology | 4 | 2.0 |
Antigens, CD/*analysis | 7 | 0.0 |
Cytokines/pharmacology | 7 | 1.0 |
Membrane Glycoproteins/analysis | 4 | 1.0 |
Salivary Glands/*immunology | 2 | 66.0 |
Sjogren's Syndrome/*immunology | 2 | 6.0 |
Analysis of Variance | 4 | 0.0 |
Homeostasis | 2 | 0.0 |
Biological Markers/blood | 3 | 0.0 |
Child, Preschool | 25 | 0.0 |
Immunoglobulins/blood | 2 | 2.0 |
Infant | 15 | 0.0 |
Chickens/*genetics | 2 | 2.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Species Specificity | 8 | 0.0 |
Interleukin-2/*therapeutic use | 24 | 23.0 |
Neoplasms/*therapy | 9 | 8.0 |
Recombinant Fusion Proteins/*therapeutic use | 2 | 10.0 |
Adjuvants, Immunologic/*therapeutic use | 3 | 3.0 |
Arthritis, Rheumatoid/*immunology | 3 | 1.0 |
Antigens, Viral/*immunology | 2 | 2.0 |
Biological Products/*therapeutic use | 3 | 20.0 |
Interleukin-6/biosynthesis | 4 | 1.0 |
Leukocytes, Mononuclear/metabolism | 3 | 1.0 |
T-Lymphocytes/*immunology | 87 | 3.0 |
Intercellular Adhesion Molecule-1/blood | 2 | 2.0 |
Interferon Type II/blood | 3 | 2.0 |
Interleukin-1/blood | 3 | 1.0 |
Interleukin-2/blood | 5 | 7.0 |
Interleukin-6/blood | 2 | 0.0 |
Receptors, Interleukin-2/blood | 3 | 4.0 |
Concanavalin A/pharmacology | 17 | 8.0 |
Interleukin-2/*biosynthesis/pharmacology | 11 | 57.0 |
Mitogens/*pharmacology | 2 | 1.0 |
Antiviral Agents/*pharmacology | 2 | 1.0 |
Cell Cycle/drug effects | 4 | 0.0 |
Cytokines/*biosynthesis | 8 | 2.0 |
Interferon Type I, Recombinant/*pharmacology | 4 | 8.0 |
Lymphocyte Activation/*drug effects | 41 | 12.0 |
Lymphocytes/drug effects/immunology | 3 | 9.0 |
Cytokines/genetics | 2 | 1.0 |
*Gene Therapy | 2 | 0.0 |
Immunotherapy | 16 | 4.0 |
Mutation | 5 | 0.0 |
B-Lymphocytes/*immunology | 25 | 3.0 |
Bone Marrow Cells | 6 | 1.0 |
Cloning, Molecular | 13 | 0.0 |
Expressed Sequence Tags | 2 | 0.0 |
Ligands | 5 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Graft Rejection/*prevention & control | 3 | 7.0 |
Antigens, CD/analysis | 14 | 0.0 |
Cytotoxicity, Immunologic/*physiology | 2 | 14.0 |
Killer Cells, Natural/drug effects/*immunology | 2 | 5.0 |
Antineoplastic Agents/*adverse effects | 3 | 5.0 |
Interleukin-2/*adverse effects | 6 | 60.0 |
Cytokines/secretion | 3 | 3.0 |
Immunotherapy/*methods | 10 | 7.0 |
Interleukin-2/genetics/immunology | 2 | 28.0 |
Lymphatic Metastasis | 5 | 0.0 |
Immunoenzyme Techniques | 8 | 0.0 |
Interleukins/metabolism | 2 | 6.0 |
Microscopy, Confocal | 3 | 0.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 4 | 1.0 |
Cell Culture Techniques | 2 | 0.0 |
Clone Cells/drug effects/immunology | 3 | 75.0 |
Interleukin-2/immunology | 19 | 17.0 |
Synovial Fluid/*immunology | 2 | 3.0 |
T-Lymphocytes/*drug effects/immunology | 6 | 6.0 |
Apoptosis/drug effects | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Erythropoietin/*pharmacology | 2 | 1.0 |
Gene Expression Regulation/drug effects | 8 | 0.0 |
*Milk Proteins | 2 | 0.0 |
Precipitin Tests | 12 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 3 | 0.0 |
*Proto-Oncogene Proteins | 4 | 0.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Signal Transduction/drug effects | 4 | 0.0 |
Cyclosporine/*therapeutic use | 2 | 6.0 |
*Kidney Transplantation | 5 | 1.0 |
Thymus Gland/cytology/immunology | 2 | 4.0 |
Antigen-Presenting Cells/physiology | 4 | 7.0 |
Prognosis | 9 | 0.0 |
Double-Blind Method | 3 | 0.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 4 | 0.0 |
Cisplatin/administration & dosage | 2 | 0.0 |
Combined Modality Therapy | 20 | 1.0 |
Infusions, Intravenous | 12 | 1.0 |
Injections, Subcutaneous | 6 | 1.0 |
Remission Induction | 11 | 1.0 |
Survival Rate | 8 | 0.0 |
Biotechnology | 2 | 7.0 |
Glycosylation | 2 | 0.0 |
Hamsters | 10 | 0.0 |
Bone Marrow Transplantation | 9 | 3.0 |
Killer Cells, Natural/immunology | 27 | 6.0 |
Neuroblastoma/immunology/*therapy | 2 | 66.0 |
Transplantation, Autologous | 6 | 1.0 |
Apoptosis | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 10 | 0.0 |
Mesocricetus | 2 | 1.0 |
Molecular Weight | 22 | 0.0 |
Pregnancy | 7 | 0.0 |
Biological Transport | 4 | 0.0 |
Autoradiography | 3 | 0.0 |
Iodine Radioisotopes/*diagnostic use | 3 | 5.0 |
Receptors, Interleukin-2/metabolism | 16 | 8.0 |
Sensitivity and Specificity | 8 | 0.0 |
Antigens, CD/immunology | 4 | 0.0 |
Antineoplastic Agents/*therapeutic use | 4 | 1.0 |
Drug Screening Assays, Antitumor | 5 | 1.0 |
Immunotherapy, Active/*methods | 2 | 18.0 |
Immunotherapy, Adoptive/*methods | 5 | 12.0 |
Mice, Inbred BALB C | 28 | 0.0 |
Mice, Nude | 12 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Interleukin-2/*diagnostic use | 3 | 75.0 |
Lymphocytes/*pathology | 2 | 4.0 |
Cytokines/*pharmacology | 7 | 1.0 |
Interleukin-7/pharmacology | 2 | 4.0 |
Killer Cells, Natural/*drug effects | 7 | 24.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Phenotype | 43 | 0.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
Cytotoxicity, Immunologic/drug effects | 11 | 9.0 |
Killer Cells, Natural/*drug effects/immunology | 8 | 29.0 |
Cyclosporine/pharmacology | 4 | 1.0 |
DNA Primers/genetics | 2 | 0.0 |
Dexamethasone/pharmacology | 3 | 0.0 |
Gene Expression/drug effects | 3 | 0.0 |
Jurkat Cells | 6 | 0.0 |
T-Lymphocytes/drug effects/*immunology/metabolism | 2 | 8.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Cytokines/*secretion | 2 | 3.0 |
Interleukin-2/secretion | 7 | 9.0 |
Multiple Sclerosis/*immunology | 2 | 1.0 |
Tumor Necrosis Factor-alpha/secretion | 5 | 4.0 |
Drug Evaluation | 10 | 4.0 |
Drug Therapy, Combination | 7 | 0.0 |
Lymphokines/secretion | 2 | 5.0 |
Antigens, CD28/immunology | 4 | 2.0 |
Chromium Radioisotopes/diagnostic use | 2 | 10.0 |
Interleukin-10/immunology | 2 | 7.0 |
Lupus Erythematosus, Systemic/*immunology | 4 | 2.0 |
Neutralization Tests | 2 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology | 7 | 0.0 |
Melanoma/*immunology | 6 | 7.0 |
Disease-Free Survival | 2 | 0.0 |
Antigens, CD3/metabolism | 3 | 1.0 |
Calcium/metabolism | 10 | 0.0 |
Cytotoxicity, Immunologic | 63 | 6.0 |
Killer Cells, Natural/cytology/*immunology/metabolism | 2 | 50.0 |
Caco-2 Cells | 2 | 0.0 |
Cell Communication | 10 | 3.0 |
Chick Embryo | 2 | 0.0 |
Rats | 28 | 0.0 |
Infant, Newborn | 7 | 0.0 |
Interleukin-2/*genetics | 17 | 26.0 |
T-Lymphocytes/*metabolism | 14 | 3.0 |
Lymphocyte Subsets | 3 | 1.0 |
Cell Separation | 21 | 1.0 |
*Lymphocyte Activation | 76 | 5.0 |
Disease Progression | 9 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Signal Transduction/genetics | 2 | 0.0 |
Immunoglobulin E/blood | 3 | 2.0 |
T-Lymphocyte Subsets/immunology | 6 | 1.0 |
Drug Administration Schedule | 11 | 1.0 |
Interleukin-2/administration & dosage/*therapeutic use | 3 | 11.0 |
Solubility | 13 | 0.0 |
Th2 Cells/immunology | 2 | 1.0 |
Cell Line/drug effects | 2 | 4.0 |
Immunity, Cellular/drug effects | 4 | 6.0 |
Killer Cells, Lymphokine-Activated/*drug effects | 3 | 42.0 |
Killer Cells, Natural/drug effects | 7 | 20.0 |
T-Lymphocytes, Cytotoxic/*drug effects/immunology | 3 | 33.0 |
Lymphocyte Activation/drug effects | 46 | 8.0 |
Spleen/cytology | 5 | 2.0 |
Tumor Necrosis Factor-alpha/pharmacology | 10 | 0.0 |
Apoptosis/*immunology | 2 | 1.0 |
Macrophages/*immunology | 5 | 2.0 |
Antigens, CD34/*metabolism | 2 | 1.0 |
Cell Differentiation | 27 | 0.0 |
Thymus Gland/cytology | 3 | 3.0 |
HIV Seronegativity | 2 | 1.0 |
Leukocytes, Mononuclear/chemistry | 2 | 7.0 |
Antibody-Dependent Cell Cytotoxicity/immunology | 2 | 15.0 |
Gangliosides/*immunology | 3 | 15.0 |
Interleukin-2/metabolism/*pharmacology | 3 | 60.0 |
Lymphocyte Activation/*drug effects/immunology | 2 | 9.0 |
Cell Division/immunology | 4 | 1.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Fluorescent Antibody Technique | 18 | 0.0 |
Graves' Disease/*metabolism | 2 | 18.0 |
Administration, Intranasal | 2 | 2.0 |
Injections, Intradermal | 2 | 4.0 |
Interleukin-2/biosynthesis/genetics | 2 | 5.0 |
Lung Neoplasms/secondary/therapy | 2 | 22.0 |
Binding Sites | 5 | 0.0 |
Chromosome Mapping | 6 | 0.0 |
Linkage (Genetics) | 4 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
T-Lymphocytes/*drug effects | 5 | 7.0 |
Transcription Factors/metabolism | 2 | 0.0 |
BCG Vaccine/*therapeutic use | 2 | 11.0 |
Cytokines/biosynthesis | 8 | 1.0 |
Interleukin-10/blood | 2 | 2.0 |
Th2 Cells/metabolism | 2 | 4.0 |
Arthritis, Rheumatoid/*genetics | 2 | 2.0 |
Cytokines/*genetics | 10 | 7.0 |
Interleukin-2/*antagonists & inhibitors | 3 | 100.0 |
Cytokines/metabolism | 4 | 0.0 |
Lymphocyte Activation/*physiology | 4 | 4.0 |
Monocytes/immunology | 13 | 3.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
S Phase | 2 | 0.0 |
Forecasting | 2 | 0.0 |
Killer Cells, Lymphokine-Activated/*transplantation | 3 | 42.0 |
Neoplasms/genetics/immunology/*therapy | 2 | 66.0 |
Complement 3/metabolism | 2 | 0.0 |
Hypersensitivity, Delayed | 2 | 3.0 |
Leukocyte Count | 14 | 0.0 |
Receptors, Interleukin-2/*immunology | 13 | 30.0 |
Neoplasm Metastasis | 5 | 0.0 |
Neoplasm Transplantation | 7 | 0.0 |
Antigens, Differentiation/immunology | 2 | 1.0 |
T-Lymphocytes, Helper-Inducer/immunology | 9 | 4.0 |
Antigen-Presenting Cells/*immunology | 3 | 2.0 |
Interleukin-4/biosynthesis | 3 | 2.0 |
Antibodies/*immunology | 3 | 2.0 |
In Situ Hybridization | 7 | 0.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
Remission, Spontaneous | 2 | 2.0 |
*Adaptor Proteins, Signal Transducing | 3 | 0.0 |
Cross-Linking Reagents | 8 | 2.0 |
Protein-Tyrosine Kinase/*metabolism | 4 | 0.0 |
T-Lymphocytes | 7 | 2.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Glucocorticoids/pharmacology | 2 | 1.0 |
Italy | 3 | 0.0 |
Mitogens | 2 | 2.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Blotting, Southern | 6 | 0.0 |
Cytotoxicity, Immunologic/immunology | 6 | 8.0 |
Freezing | 2 | 2.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
RNA, Messenger/*analysis | 4 | 0.0 |
Recurrence | 5 | 0.0 |
Tumor Necrosis Factor-alpha/*metabolism | 4 | 0.0 |
*ADP Ribose Transferases | 9 | 11.0 |
*Bacterial Toxins | 10 | 6.0 |
*Virulence Factors | 9 | 10.0 |
Hematopoietic Stem Cell Transplantation | 3 | 1.0 |
Immunotherapy, Adoptive | 6 | 8.0 |
Leukapheresis | 3 | 2.0 |
Platelet Count | 2 | 0.0 |
Interleukin-2/*metabolism | 17 | 36.0 |
Signal Transduction/*immunology | 2 | 0.0 |
T-Lymphocyte Subsets/*immunology | 11 | 2.0 |
T-Lymphocytes/*immunology/metabolism | 15 | 9.0 |
Cell Differentiation/immunology | 2 | 0.0 |
Dogs | 3 | 0.0 |
Hematopoietic Stem Cells/cytology/immunology | 2 | 6.0 |
Cycloheximide/pharmacology | 7 | 1.0 |
Cyclosporine/*pharmacology | 6 | 5.0 |
Gene Expression Regulation | 9 | 0.0 |
Leukocytes, Mononuclear/*drug effects | 2 | 11.0 |
*Nuclear Proteins | 4 | 0.0 |
Phorbol Esters/pharmacology | 6 | 5.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
RNA, Messenger | 2 | 0.0 |
*Gene Expression | 2 | 0.0 |
Interferon Type II/*genetics | 2 | 3.0 |
Interleukin-4/genetics | 3 | 7.0 |
Interleukins/*genetics | 2 | 7.0 |
Receptors, Interleukin-2/drug effects/metabolism | 3 | 30.0 |
3T3 Cells | 2 | 0.0 |
RNA, Messenger/biosynthesis | 8 | 0.0 |
*Transfection | 3 | 1.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Creatinine/blood | 3 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Interleukin-2/*administration & dosage/adverse effects | 6 | 50.0 |
Kidney Neoplasms/immunology/*therapy | 2 | 28.0 |
Killer Cells, Lymphokine-Activated/*immunology | 11 | 15.0 |
Enzyme Activation | 9 | 0.0 |
Polyenes/*pharmacology | 5 | 31.0 |
Receptors, Interleukin-2/*physiology | 8 | 36.0 |
Serine/metabolism | 2 | 0.0 |
Sirolimus | 5 | 11.0 |
*Immunity, Cellular | 2 | 1.0 |
Immunization | 4 | 1.0 |
CD4-Positive T-Lymphocytes/*physiology | 3 | 3.0 |
CD8-Positive T-Lymphocytes/*physiology | 2 | 11.0 |
Carcinoma, Squamous Cell/*immunology | 2 | 7.0 |
Cell Line, Transformed | 4 | 0.0 |
Cytokines | 14 | 13.0 |
Head and Neck Neoplasms/*immunology | 3 | 27.0 |
Intercellular Adhesion Molecule-1/analysis | 2 | 1.0 |
Interferon-alpha/administration & dosage | 2 | 18.0 |
Tumor Cells, Cultured/drug effects | 4 | 0.0 |
Tumor Necrosis Factor-alpha/*analysis | 2 | 0.0 |
Administration, Oral | 2 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
DNA/analysis | 3 | 0.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
Gene Therapy/*methods | 4 | 0.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Immunosuppression/*methods | 2 | 8.0 |
Interleukin-2/biosynthesis/immunology | 3 | 33.0 |
Lac Operon | 2 | 1.0 |
Plasmids | 9 | 0.0 |
*Recombination, Genetic | 2 | 0.0 |
Spleen/cytology/immunology | 3 | 4.0 |
Cell Membrane/metabolism | 5 | 0.0 |
Receptors, Interleukin-2/chemistry/*metabolism | 2 | 28.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Adjuvants, Immunologic/*pharmacology | 8 | 4.0 |
Immunity, Cellular/*drug effects | 3 | 7.0 |
Calcineurin | 2 | 10.0 |
Calcium/*physiology | 5 | 4.0 |
Transcription Factors/*physiology | 2 | 0.0 |
HIV-1/*physiology | 3 | 0.0 |
*Virus Replication | 3 | 1.0 |
Urine/cytology | 3 | 27.0 |
Vaccination | 5 | 3.0 |
Vaccines, Synthetic/immunology | 2 | 6.0 |
Chronic Disease | 8 | 0.0 |
Interferon Type II/immunology | 3 | 3.0 |
Interleukin-1/immunology | 3 | 6.0 |
Rats, Inbred Lew | 3 | 1.0 |
Tumor Necrosis Factor-alpha/immunology | 2 | 1.0 |
Antigens, Neoplasm/immunology | 6 | 4.0 |
B-Lymphocytes/immunology | 15 | 2.0 |
*Cytotoxicity, Immunologic | 22 | 4.0 |
Hybridomas/*immunology | 3 | 10.0 |
Neoplasms/*immunology | 4 | 3.0 |
Leukemia, Erythroblastic, Acute | 2 | 2.0 |
Receptors, Interleukin-4 | 6 | 8.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Antigens/*immunology | 7 | 9.0 |
Clonal Anergy/*immunology | 3 | 12.0 |
Interleukin-4/*immunology | 2 | 11.0 |
Tetanus Toxin/*immunology | 2 | 50.0 |
Autoimmunity | 2 | 1.0 |
Immune Tolerance | 10 | 3.0 |
Immunosuppression | 8 | 4.0 |
Immunosuppressive Agents/therapeutic use | 2 | 0.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
*Herpesvirus 4, Human | 3 | 8.0 |
Interleukins/*biosynthesis | 2 | 8.0 |
Interleukin-2/*adverse effects/therapeutic use | 3 | 37.0 |
Neoplasm Staging | 6 | 0.0 |
Recombinant Proteins/administration & dosage | 3 | 3.0 |
HIV-1 | 2 | 1.0 |
Haplotypes | 2 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Carcinoma, Squamous Cell/*therapy | 2 | 22.0 |
Head and Neck Neoplasms/*therapy | 2 | 33.0 |
CD40 Ligand | 3 | 1.0 |
Down-Regulation | 6 | 0.0 |
Interleukin-4/immunology | 3 | 5.0 |
CD8-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
Interleukin-4/*biosynthesis | 3 | 5.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Interferons/pharmacology | 3 | 4.0 |
Interleukins/pharmacology | 7 | 10.0 |
Tumor Stem Cells/*drug effects/pathology | 2 | 22.0 |
Antibodies, Monoclonal/pharmacology | 6 | 0.0 |
Hypersensitivity, Immediate/*immunology | 2 | 7.0 |
Drugs, Chinese Herbal/*pharmacology | 2 | 4.0 |
Mites/*immunology | 7 | 14.0 |
Antigens, CD3 | 35 | 7.0 |
DNA/biosynthesis | 12 | 2.0 |
Antigens, CD/genetics | 3 | 2.0 |
Gene Rearrangement | 2 | 0.0 |
Cell Death/drug effects | 2 | 1.0 |
Chimeric Proteins/*pharmacology | 2 | 28.0 |
*Recombinant Fusion Proteins | 2 | 3.0 |
Recombinant Proteins/pharmacology | 34 | 1.0 |
Interleukin-1/*pharmacology | 4 | 0.0 |
Monocytes/drug effects/metabolism | 2 | 2.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
Interleukin-2/*pharmacology/therapeutic use | 5 | 45.0 |
Interleukin-6/metabolism | 3 | 1.0 |
Transcription, Genetic | 11 | 0.0 |
Interferon Type II/biosynthesis/secretion | 2 | 20.0 |
Tetanus Toxoid/immunology | 2 | 2.0 |
Cats | 2 | 0.0 |
Cattle | 8 | 0.0 |
Cytokines/genetics/*metabolism | 2 | 5.0 |
RNA-Directed DNA Polymerase | 2 | 1.0 |
Reproducibility of Results | 7 | 0.0 |
Cell Division/radiation effects | 2 | 4.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Peptides/*genetics | 2 | 2.0 |
Receptors, Interleukin-2/genetics/metabolism | 2 | 14.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Cytokines/physiology | 3 | 1.0 |
Colony-Forming Units Assay | 10 | 1.0 |
*Immune Tolerance | 4 | 2.0 |
Lymphocyte Culture Test, Mixed | 25 | 3.0 |
T-Lymphocytes/cytology | 4 | 4.0 |
HLA Antigens/immunology | 3 | 1.0 |
Interleukin-2/physiology | 19 | 22.0 |
Evaluation Studies | 2 | 0.0 |
Neuroblastoma/immunology/*secondary/*therapy | 2 | 100.0 |
T-Lymphocytes/drug effects | 2 | 3.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
*Enhancer Elements (Genetics) | 2 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Immunosuppressive Agents/*pharmacology | 8 | 3.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Signal Transduction/physiology | 2 | 0.0 |
Aging/*physiology | 2 | 0.0 |
Mice, Inbred Strains | 8 | 0.0 |
Feasibility Studies | 3 | 1.0 |
Receptors, Interleukin-2/biosynthesis | 4 | 3.0 |
Quality of Life | 2 | 1.0 |
Immunoblotting | 3 | 0.0 |
Antibodies, Monoclonal/immunology | 21 | 1.0 |
Antigens, CD3/immunology | 3 | 1.0 |
Interferon Type II/secretion | 4 | 3.0 |
Lymphocytes, Tumor-Infiltrating/*immunology | 5 | 7.0 |
Antibody Formation/drug effects | 9 | 18.0 |
Interleukin-2/biosynthesis/pharmacology | 7 | 33.0 |
Lymph Nodes/cytology | 3 | 7.0 |
*Lymphocyte Activation/drug effects | 12 | 11.0 |
T-Lymphocytes/drug effects/immunology | 7 | 8.0 |
Killer Cells, Lymphokine-Activated/immunology | 9 | 13.0 |
Antiviral Agents/*therapeutic use | 2 | 1.0 |
*Bone Marrow Transplantation | 15 | 3.0 |
RNA/analysis | 3 | 1.0 |
Interferon Alfa-2a/administration & dosage | 2 | 50.0 |
Interleukin-2/administration & dosage | 7 | 36.0 |
Killer Cells, Natural/*metabolism | 2 | 3.0 |
Escherichia coli/*genetics | 2 | 2.0 |
*Recombinant Proteins | 2 | 14.0 |
B-Lymphocytes/*cytology | 2 | 3.0 |
Calcium/*metabolism | 6 | 0.0 |
Cytoplasm/metabolism | 3 | 0.0 |
Pertussis Toxin | 2 | 1.0 |
Protein Kinase C/metabolism | 2 | 0.0 |
Staphylococcus aureus/immunology | 6 | 5.0 |
Staurosporine | 2 | 2.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
Gestational Age | 3 | 0.0 |
B-Lymphocytes/*physiology | 3 | 2.0 |
Staphylococcus aureus/*immunology | 2 | 2.0 |
T-Lymphocytes/*physiology | 12 | 4.0 |
Antibody Formation/immunology | 2 | 4.0 |
Antigens, Protozoan/immunology | 3 | 9.0 |
Antibody Formation | 11 | 2.0 |
Asthma/*blood/immunology | 2 | 40.0 |
*Epitopes | 2 | 1.0 |
RNA, Viral/blood | 2 | 0.0 |
Blotting, Northern | 10 | 0.0 |
DNA Probes | 4 | 0.0 |
Interleukin-2/*analysis | 7 | 53.0 |
Stimulation, Chemical | 5 | 1.0 |
Thymidine/metabolism | 6 | 1.0 |
Tritium | 2 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Interleukins/genetics | 2 | 12.0 |
*Immunosuppressive Agents | 3 | 23.0 |
Hypersensitivity, Delayed/immunology | 4 | 6.0 |
Interleukin-2/*administration & dosage | 6 | 23.0 |
Kidney Neoplasms/immunology/pathology/*therapy | 2 | 66.0 |
Cholera Toxin/pharmacology | 4 | 5.0 |
Growth Substances/*physiology | 2 | 1.0 |
Radioimmunoassay | 9 | 0.0 |
*Endocytosis | 3 | 1.0 |
Endosomes/metabolism | 2 | 1.0 |
Iodine Radioisotopes | 2 | 0.0 |
Macromolecular Substances | 5 | 0.0 |
Immunoglobulin G/biosynthesis | 9 | 5.0 |
Lymphocyte Activation/drug effects/*physiology | 3 | 17.0 |
Pokeweed Mitogens/pharmacology | 5 | 6.0 |
Antigens, CD/*physiology | 10 | 3.0 |
T-Lymphocytes/*cytology | 6 | 6.0 |
Interleukin-1/genetics | 2 | 2.0 |
Liver/*immunology | 2 | 5.0 |
Kidney/metabolism | 2 | 0.0 |
Major Histocompatibility Complex/immunology | 3 | 6.0 |
Antibody-Dependent Cell Cytotoxicity | 4 | 4.0 |
Binding, Competitive | 16 | 0.0 |
Complement/immunology | 3 | 3.0 |
Immunoglobulin G/immunology | 3 | 0.0 |
Cytotoxicity, Immunologic/physiology | 3 | 60.0 |
Lymphocyte Activation/physiology | 2 | 2.0 |
Immunity/*drug effects | 2 | 14.0 |
Phagocytosis/drug effects | 2 | 2.0 |
Graft Rejection | 4 | 2.0 |
Interleukin-10/*biosynthesis | 2 | 3.0 |
Interleukin-4/*pharmacology | 7 | 3.0 |
Interleukin-6/*biosynthesis | 2 | 1.0 |
Transplantation, Homologous | 11 | 1.0 |
Thyroid Gland/drug effects/*physiology | 2 | 40.0 |
Carcinoma, Renal Cell/mortality/secondary/*therapy | 2 | 100.0 |
Kidney Neoplasms/mortality/*therapy | 2 | 66.0 |
Killer Cells, Lymphokine-Activated | 2 | 25.0 |
Lymphocyte Transfusion | 3 | 10.0 |
Protein Kinases/metabolism | 4 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Receptors, Antigen, T-Cell/genetics | 2 | 2.0 |
Calcimycin/pharmacology | 9 | 3.0 |
Epitopes | 8 | 0.0 |
Interleukin-4/*metabolism | 2 | 5.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 10 | 6.0 |
Cytosol/metabolism | 2 | 0.0 |
Killer Cells, Natural | 2 | 4.0 |
Models, Biological | 7 | 0.0 |
*Graft Rejection | 3 | 3.0 |
Lymphocyte Activation/drug effects/immunology | 3 | 5.0 |
Lymphocyte Subsets/immunology | 3 | 2.0 |
Receptors, Interleukin-2/genetics/*physiology | 3 | 75.0 |
Disease Susceptibility | 2 | 0.0 |
Interleukin-2/*genetics/metabolism | 2 | 20.0 |
Luciferases/metabolism | 2 | 0.0 |
Antigens, Dermatophagoides | 3 | 5.0 |
Antigens/immunology | 4 | 2.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 2 | 0.0 |
Receptors, Antigen, T-Cell/metabolism | 5 | 2.0 |
Tacrolimus/*pharmacology | 3 | 8.0 |
Tetradecanoylphorbol Acetate | 3 | 4.0 |
Antibody-Producing Cells/cytology/immunology | 2 | 66.0 |
B-Lymphocytes/*cytology/immunology | 3 | 9.0 |
Lymphocyte Cooperation | 8 | 10.0 |
Major Histocompatibility Complex | 4 | 1.0 |
Mitosis | 2 | 0.0 |
T-Lymphocytes/immunology/*metabolism | 5 | 5.0 |
Growth Substances/physiology | 4 | 3.0 |
*Immunotherapy, Adoptive | 6 | 9.0 |
Cell Adhesion | 11 | 0.0 |
Lymphokines/*pharmacology | 8 | 3.0 |
Ovalbumin/pharmacology | 2 | 25.0 |
Receptors, Interleukin-2/physiology | 13 | 27.0 |
Cell Differentiation/drug effects | 15 | 1.0 |
Prolactin/*pharmacology | 2 | 2.0 |
Receptors, IgG/immunology | 2 | 5.0 |
*Chromosome Mapping | 3 | 0.0 |
*Chromosomes, Human, Pair 4 | 2 | 0.0 |
Hybrid Cells | 4 | 0.0 |
RNA/biosynthesis | 3 | 3.0 |
Tacrolimus/pharmacology | 2 | 4.0 |
Receptors, Interleukin-2/*genetics/metabolism | 2 | 33.0 |
Hodgkin Disease/*immunology | 4 | 14.0 |
Hyperplasia | 2 | 0.0 |
Interleukin-2/biosynthesis/*genetics | 4 | 22.0 |
Leukemia/immunology/*therapy | 2 | 22.0 |
Receptors, Interleukin-2/genetics | 7 | 18.0 |
*Antibody-Dependent Cell Cytotoxicity | 2 | 4.0 |
HIV Infections/*immunology | 5 | 1.0 |
Genes, Structural | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Depression, Chemical | 5 | 2.0 |
Antigens, CD8/*immunology | 2 | 3.0 |
Lymphocytes, Tumor-Infiltrating/immunology/pathology | 2 | 28.0 |
Influenza Vaccines/*immunology | 4 | 20.0 |
Leukocytes, Mononuclear/immunology | 8 | 2.0 |
*Bone Marrow Cells | 3 | 1.0 |
Colony-Stimulating Factors/*pharmacology | 2 | 4.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Drug Interactions | 4 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 2 | 0.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Immunoglobulins, Heavy-Chain | 2 | 28.0 |
Leukemia, B-Cell/*therapy | 2 | 50.0 |
Gene Expression/immunology | 2 | 2.0 |
Interleukin-2/biosynthesis/*physiology | 7 | 87.0 |
Interleukin-7/*physiology | 3 | 33.0 |
Sezary Syndrome/immunology/*pathology | 2 | 50.0 |
Skin Neoplasms/immunology/*pathology | 2 | 7.0 |
Bucladesine/pharmacology | 3 | 1.0 |
Cyclic AMP/biosynthesis | 3 | 2.0 |
Mice, Inbred C3H | 4 | 0.0 |
Cytomegalovirus/*immunology | 2 | 3.0 |
Hydrocortisone/blood | 2 | 0.0 |
Lymphocytes/immunology | 13 | 3.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 4 | 0.0 |
Interleukin-2/administration & dosage/*pharmacology | 4 | 80.0 |
Administration, Intravesical | 2 | 7.0 |
Immunoglobulin G/analysis | 3 | 0.0 |
Osmolar Concentration | 2 | 0.0 |
Tumor Necrosis Factor-alpha/urine | 2 | 50.0 |
Acquired Immunodeficiency Syndrome/*immunology | 4 | 1.0 |
Interferon-alpha/*therapeutic use | 4 | 6.0 |
Leukemia/therapy | 2 | 5.0 |
Injections, Intralesional | 2 | 4.0 |
Killer Cells, Natural/drug effects/immunology | 3 | 9.0 |
Antibodies, Monoclonal/*immunology | 17 | 2.0 |
Cytotoxicity, Immunologic/*immunology | 2 | 4.0 |
Recombinant Fusion Proteins/*immunology | 2 | 9.0 |
Recombinant Proteins/immunology | 7 | 2.0 |
Interleukin-2/*administration & dosage/therapeutic use | 2 | 66.0 |
Spleen/*immunology | 2 | 9.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Interleukin-12 | 2 | 11.0 |
Interleukin-2/*physiology | 26 | 35.0 |
Tumor Cells, Cultured/immunology | 3 | 3.0 |
Rabbits | 4 | 0.0 |
Xenopus | 2 | 0.0 |
Hypersensitivity/*immunology | 4 | 8.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
Interleukin-1/*biosynthesis | 6 | 4.0 |
Leukocytes, Mononuclear/*metabolism | 6 | 4.0 |
Antigens, CD2 | 15 | 3.0 |
Cell Membrane/immunology | 2 | 0.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
T-Lymphocytes/*immunology/pathology | 3 | 5.0 |
Cell Separation/*methods | 3 | 2.0 |
Plastics | 3 | 9.0 |
Leukocytes, Mononuclear/*immunology | 4 | 2.0 |
Receptors, Antigen, T-Cell, gamma-delta/analysis | 2 | 5.0 |
Antigens, CD/*immunology | 7 | 1.0 |
Antigens, CD5 | 4 | 1.0 |
Antigens, CD28 | 4 | 2.0 |
Protein Kinase C/antagonists & inhibitors | 3 | 2.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Culture Media | 15 | 2.0 |
Lymphocytes/*immunology/metabolism | 3 | 13.0 |
Skin/*immunology | 2 | 1.0 |
Kidney Neoplasms/drug therapy/*immunology | 2 | 100.0 |
Killer Cells, Lymphokine-Activated/drug effects | 3 | 27.0 |
Leukocytes, Mononuclear/drug effects | 3 | 7.0 |
Melanoma/drug therapy/*immunology | 2 | 66.0 |
Recombinant Proteins/therapeutic use | 6 | 1.0 |
Tumor Necrosis Factor-alpha/drug effects | 2 | 33.0 |
T-Lymphocytes/*pathology | 6 | 8.0 |
Colitis, Ulcerative/*immunology | 2 | 5.0 |
Interferon Type II/*pharmacology | 3 | 0.0 |
Antigens, CD3/physiology | 3 | 4.0 |
Interleukin-4/pharmacology | 7 | 2.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
B-Lymphocytes | 4 | 2.0 |
Antibodies/analysis | 2 | 1.0 |
Iodine Radioisotopes/diagnostic use | 5 | 1.0 |
Antigens, Surface/*analysis | 7 | 3.0 |
Membrane Glycoproteins/*analysis | 2 | 1.0 |
Receptors, Interleukin-2/*analysis | 8 | 11.0 |
Cytotoxicity, Immunologic/*drug effects | 5 | 6.0 |
Interleukins/*pharmacology | 8 | 10.0 |
Anthranilic Acids/*pharmacology | 3 | 50.0 |
Asthma/immunology | 3 | 8.0 |
Glycoproteins | 2 | 8.0 |
Mites/immunology | 2 | 5.0 |
Ovalbumin/immunology | 2 | 4.0 |
Immunotoxins/*therapeutic use | 2 | 4.0 |
Interleukin-2/metabolism/pharmacology | 2 | 28.0 |
T-Lymphocytes/drug effects/*metabolism | 4 | 8.0 |
Carrier Proteins/*immunology | 2 | 4.0 |
Epitopes/immunology | 6 | 1.0 |
Antigens, CD3/*immunology | 2 | 1.0 |
Magnetics | 2 | 2.0 |
Microspheres | 2 | 1.0 |
Antigens, Differentiation, T-Lymphocyte | 26 | 9.0 |
Immunologic Memory | 6 | 2.0 |
Isoantigens | 2 | 7.0 |
Membrane Proteins/*analysis | 2 | 2.0 |
Bone Marrow/immunology | 4 | 3.0 |
Immunoglobulin Isotypes/*biosynthesis | 2 | 66.0 |
Immunoglobulin M/biosynthesis | 4 | 4.0 |
Lymph Nodes/immunology | 2 | 2.0 |
Spleen/immunology | 6 | 3.0 |
Chromatography, Gel | 4 | 0.0 |
DNA | 2 | 0.0 |
Leukemia | 2 | 2.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Kidney Neoplasms/secondary/*therapy | 2 | 100.0 |
Carcinoma/*immunology | 2 | 6.0 |
Killer Cells, Natural/cytology | 2 | 8.0 |
Ovarian Neoplasms/*immunology | 2 | 6.0 |
Lymph Nodes/pathology | 3 | 1.0 |
Immunoglobulins/*biosynthesis | 6 | 13.0 |
Lymphocytes, Tumor-Infiltrating | 2 | 12.0 |
Recombinant Proteins/adverse effects | 3 | 42.0 |
Antibodies, Monoclonal/diagnostic use | 19 | 2.0 |
Interleukin-6/analysis | 2 | 2.0 |
Bladder Neoplasms/*therapy | 2 | 22.0 |
Receptors, Antigen, T-Cell | 5 | 12.0 |
*Photopheresis | 2 | 22.0 |
Cell Cycle | 6 | 0.0 |
T-Lymphocytes/physiology | 5 | 4.0 |
Interferons/*pharmacology | 2 | 2.0 |
Receptors, Interleukin-2/drug effects | 2 | 20.0 |
Antigens, CD57 | 3 | 4.0 |
Antigens, CD7 | 4 | 3.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 12 | 5.0 |
T-Lymphocyte Subsets/*physiology | 4 | 13.0 |
B-Lymphocytes/*drug effects | 2 | 10.0 |
Interleukin-2/*genetics/therapeutic use | 2 | 100.0 |
Lymphokines/physiology | 3 | 3.0 |
Adenocarcinoma/*immunology | 2 | 5.0 |
Lung Neoplasms/*immunology | 3 | 6.0 |
Interleukin-2/genetics/*therapeutic use | 2 | 50.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Oligonucleotide Probes | 3 | 0.0 |
*Cell Division | 3 | 1.0 |
Chromatography, Affinity | 2 | 0.0 |
Lymphocytes/*metabolism | 4 | 2.0 |
Neoplasms/*metabolism | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 13 | 3.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 3 | 3.0 |
Leukocyte Count/drug effects | 2 | 1.0 |
Neoplasms/therapy | 2 | 4.0 |
Lipopolysaccharides/pharmacology | 4 | 0.0 |
Killer Cells, Lymphokine-Activated/drug effects/*immunology | 2 | 22.0 |
Immunoglobulin M/metabolism | 3 | 3.0 |
Inflammation/immunology | 2 | 1.0 |
Chimera | 3 | 1.0 |
Interleukin-2/*administration & dosage/adverse effects/therapeutic use | 2 | 66.0 |
B-Lymphocytes/metabolism | 2 | 1.0 |
Immune Tolerance/drug effects | 3 | 11.0 |
Indomethacin/pharmacology | 10 | 4.0 |
Phytohemagglutinins | 9 | 9.0 |
Antigens, CD4/*analysis | 2 | 1.0 |
Antigens, CD45 | 10 | 4.0 |
Receptors, Transferrin/physiology | 2 | 25.0 |
Antigens, CD4 | 2 | 2.0 |
Clone Cells/immunology | 13 | 8.0 |
Immunoglobulin G/*biosynthesis | 3 | 8.0 |
Immunotherapy/methods | 2 | 2.0 |
Influenza A Virus, Human/immunology | 2 | 8.0 |
Killer Cells, Natural/drug effects/physiology | 2 | 66.0 |
Cell Division/*physiology | 2 | 1.0 |
B-Lymphocytes/drug effects/*immunology | 3 | 9.0 |
Neoplasms/pathology/*therapy | 3 | 21.0 |
Immunization, Passive | 7 | 8.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 4 | 0.0 |
Interleukin-1/biosynthesis | 5 | 2.0 |
Lymphocytes, Tumor-Infiltrating/immunology | 2 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/*physiology | 7 | 4.0 |
Interleukin-1/pharmacology | 8 | 1.0 |
Receptors, Antigen, T-Cell/*physiology | 9 | 5.0 |
Receptors, Immunologic/*physiology | 9 | 5.0 |
Recombinant Proteins | 14 | 1.0 |
Immunoglobulins/biosynthesis | 2 | 1.0 |
Phytohemagglutinins/immunology | 2 | 4.0 |
Antigens, CD45/analysis | 2 | 0.0 |
Neoplasms/immunology/*therapy | 7 | 13.0 |
Immunoglobulin E/*biosynthesis | 3 | 6.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 6 | 3.0 |
Antigens, Differentiation, T-Lymphocyte/physiology | 6 | 7.0 |
*Cell Communication | 3 | 3.0 |
Receptors, Immunologic/physiology | 13 | 11.0 |
Endocytosis | 4 | 1.0 |
Receptors, Immunologic/metabolism | 6 | 3.0 |
Recombinant Proteins/metabolism/pharmacology | 3 | 2.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
CHO Cells | 2 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Cell Membrane/physiology | 3 | 2.0 |
Membrane Potentials | 2 | 0.0 |
Interleukin-2/*biosynthesis/genetics | 2 | 11.0 |
Carcinoma, Renal Cell/*therapy | 3 | 30.0 |
Kidney Neoplasms/*therapy | 3 | 21.0 |
Melanoma/secondary/*therapy | 2 | 66.0 |
Interleukin-2/administration & dosage/adverse effects/*therapeutic use | 4 | 80.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine | 2 | 3.0 |
B-Lymphocytes/cytology/*physiology | 2 | 33.0 |
Isoquinolines/pharmacology | 2 | 1.0 |
Phorbol 12,13-Dibutyrate/pharmacology | 2 | 3.0 |
Piperazines/pharmacology | 2 | 1.0 |
*HIV-1 | 3 | 0.0 |
T-Lymphocytes/cytology/*drug effects/metabolism | 2 | 25.0 |
Histocompatibility Antigens/*immunology | 2 | 8.0 |
Receptors, Mitogen/metabolism | 2 | 10.0 |
Melanoma/*drug therapy/secondary | 2 | 66.0 |
Granulocytes/immunology | 2 | 3.0 |
Cell Transformation, Viral | 7 | 2.0 |
Interleukin-2/genetics/*physiology | 2 | 66.0 |
Hepatitis B/*immunology | 5 | 15.0 |
Antigens, CD8 | 18 | 6.0 |
Cyclosporins/pharmacology | 5 | 13.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 9 | 4.0 |
HLA-DR Antigens/*analysis | 2 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis/*physiology | 2 | 50.0 |
Cytoplasm/immunology | 2 | 2.0 |
Receptors, Antigen, T-Cell/*analysis | 2 | 3.0 |
Lymph Nodes/*immunology | 4 | 10.0 |
Rosette Formation | 10 | 3.0 |
Lymphocytes/*drug effects | 3 | 7.0 |
Receptors, Antigen, T-Cell/*immunology | 11 | 6.0 |
Leukemia/*metabolism | 2 | 4.0 |
Phosphatidylinositols/metabolism | 2 | 1.0 |
Pseudomonas aeruginosa | 2 | 11.0 |
Lymphokines/biosynthesis | 5 | 4.0 |
*Lymphocyte Depletion | 2 | 2.0 |
Burns/*immunology | 4 | 28.0 |
Protein Kinase C/physiology | 5 | 3.0 |
Receptors, Interleukin-2/*biosynthesis | 4 | 10.0 |
Antigens, Differentiation/*immunology | 5 | 3.0 |
Receptors, Interleukin-2/immunology | 4 | 6.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 8 | 8.0 |
Antigens, CD29 | 2 | 3.0 |
Antigens, CD58 | 2 | 1.0 |
Antigens, Differentiation/analysis | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/*immunology | 3 | 13.0 |
Antigens, Surface/analysis | 24 | 5.0 |
Immunosuppressive Agents | 2 | 16.0 |
Bone Marrow/*pathology | 2 | 1.0 |
Interleukin-3/biosynthesis | 2 | 22.0 |
Multiple Myeloma/blood/*therapy | 2 | 40.0 |
Recombinant Proteins/pharmacology/therapeutic use | 2 | 5.0 |
Interleukin-2/genetics/*immunology | 2 | 40.0 |
Macrophages/immunology | 4 | 1.0 |
Monocytes/metabolism | 4 | 1.0 |
Phytohemagglutinins/*pharmacology | 3 | 8.0 |
Protein Kinase C/*metabolism | 4 | 1.0 |
Abortion, Habitual/*immunology | 2 | 8.0 |
Antigens, CD/physiology | 3 | 1.0 |
Interferon Type II/*immunology | 3 | 7.0 |
Muromonab-CD3 | 2 | 25.0 |
Immunosuppressive Agents/pharmacology | 3 | 1.0 |
Receptors, Antigen, T-Cell, alpha-beta | 2 | 5.0 |
Biological Factors/secretion | 2 | 66.0 |
Luminescent Measurements | 2 | 2.0 |
Monocytes/*immunology | 8 | 1.0 |
Receptors, IgG | 3 | 2.0 |
Antigen-Presenting Cells/immunology | 5 | 1.0 |
HLA-D Antigens/*immunology | 2 | 3.0 |
Cross Reactions | 3 | 0.0 |
Adjuvants, Immunologic/pharmacology | 3 | 3.0 |
Interleukin-2/biosynthesis/*pharmacology | 2 | 40.0 |
Nephrectomy | 2 | 2.0 |
Cyclosporins/*pharmacology | 3 | 8.0 |
Mitogens/pharmacology | 15 | 5.0 |
B-Lymphocytes/*drug effects/immunology | 2 | 6.0 |
Antigen-Presenting Cells/*physiology | 3 | 8.0 |
Receptors, Antigen, T-Cell/analysis | 5 | 4.0 |
Antigens, Differentiation/*analysis | 4 | 2.0 |
Biological Response Modifiers/*therapeutic use | 2 | 8.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Receptors, Fc/analysis | 2 | 3.0 |
Receptors, IgE | 3 | 4.0 |
Antigens, Differentiation/*physiology | 3 | 3.0 |
Monocytes/physiology | 5 | 4.0 |
B-Lymphocytes/physiology | 2 | 3.0 |
Hemolytic Plaque Technique | 2 | 3.0 |
Interleukin-1/physiology | 6 | 6.0 |
Interleukin-4/physiology | 2 | 5.0 |
T-Lymphocytes/*cytology/drug effects/immunology | 2 | 25.0 |
Platelet Count/drug effects | 2 | 5.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
T-Lymphocytes/classification/*immunology | 12 | 18.0 |
Interleukin-2/*biosynthesis/immunology | 2 | 28.0 |
*Protein Biosynthesis | 3 | 0.0 |
Cerebrospinal Fluid/cytology | 2 | 8.0 |
Receptors, Antigen, T-Cell/physiology | 3 | 2.0 |
Mice, Inbred CBA | 2 | 0.0 |
Bone Marrow/immunology/pathology | 2 | 5.0 |
Lymphocytes/drug effects/*immunology | 2 | 4.0 |
Mitomycin | 3 | 6.0 |
Mitomycins/pharmacology | 3 | 10.0 |
Receptors, Immunologic/analysis | 7 | 7.0 |
*Immunization, Passive | 7 | 12.0 |
Dose-Response Relationship, Immunologic | 8 | 1.0 |
DNA, Recombinant | 2 | 1.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Hylobates | 3 | 23.0 |
Tumor Stem Cell Assay | 3 | 1.0 |
B-Lymphocytes/cytology/*immunology | 4 | 5.0 |
Lymphokines/pharmacology | 3 | 1.0 |
T-Lymphocytes/*cytology/immunology | 6 | 12.0 |
Thymus Gland/*cytology | 5 | 9.0 |
*Cytotoxicity, Immunologic/drug effects | 2 | 7.0 |
Interleukin-2/biosynthesis/metabolism | 3 | 60.0 |
Protein Kinase C/*physiology | 3 | 3.0 |
Hepatitis, Chronic/*immunology | 3 | 18.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 8 | 2.0 |
Antibodies, Monoclonal/*pharmacology | 2 | 1.0 |
B-Lymphocytes/*metabolism | 2 | 1.0 |
Immunoglobulin M/*biosynthesis | 2 | 10.0 |
Allergens/*immunology | 3 | 3.0 |
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2.0 |
Interferons/therapeutic use | 2 | 6.0 |
Biological Assay | 2 | 0.0 |
Interphase | 5 | 3.0 |
Growth Substances/*immunology | 2 | 40.0 |
Killer Cells/immunology | 2 | 7.0 |
Antibody-Producing Cells/immunology | 4 | 16.0 |
Lymphokines/*biosynthesis | 10 | 3.0 |
Antigens, Surface/*physiology | 3 | 4.0 |
Immunologic Techniques | 3 | 0.0 |
Antigens, CD56 | 3 | 4.0 |
Biological Factors/pharmacology | 4 | 21.0 |
Lymphocytes/cytology/*drug effects | 2 | 22.0 |
Hematopoietic Stem Cells/immunology | 4 | 5.0 |
Antigen-Antibody Reactions | 7 | 2.0 |
Interleukin-1/immunology/*pharmacology | 2 | 40.0 |
Interleukin-6 | 4 | 8.0 |
Lipopolysaccharides/*pharmacology | 2 | 0.0 |
Polymyxin B/pharmacology | 2 | 3.0 |
T-Lymphocytes/cytology/*immunology | 6 | 4.0 |
Receptors, Immunologic/immunology | 5 | 4.0 |
Interleukin-4 | 26 | 29.0 |
Interleukin-5 | 7 | 53.0 |
Growth Substances/pharmacology | 4 | 2.0 |
Antibody Formation/*drug effects | 4 | 20.0 |
Calcitriol/*pharmacology | 2 | 1.0 |
Phytohemagglutinins/diagnostic use | 2 | 40.0 |
Interferon Type II/pharmacology | 6 | 1.0 |
T-Lymphocytes/classification/cytology/*immunology | 3 | 37.0 |
Diglycerides/pharmacology | 2 | 5.0 |
Leukemia, Lymphocytic/*pathology | 3 | 15.0 |
Tumor Stem Cells/*pathology | 2 | 7.0 |
Principal Component Analysis | 2 | 9.0 |
Trinitrobenzenes/immunology | 3 | 25.0 |
Killer Cells/*transplantation | 2 | 100.0 |
Interferons/biosynthesis | 3 | 20.0 |
DNA Replication/drug effects | 4 | 2.0 |
Escherichia coli/genetics | 3 | 0.0 |
*Mutation | 2 | 0.0 |
Protein Denaturation | 2 | 0.0 |
*Heart Transplantation | 2 | 2.0 |
Rats, Inbred ACI | 2 | 13.0 |
Rats, Inbred F344 | 2 | 0.0 |
Antigens, Surface/*analysis/immunology | 2 | 11.0 |
Killer Cells/classification/*immunology | 3 | 100.0 |
Phagocytosis | 2 | 0.0 |
Recombinant Proteins/*immunology | 4 | 20.0 |
Interleukin-3/*pharmacology | 2 | 1.0 |
Lymphoma, Non-Hodgkin/*immunology | 2 | 9.0 |
Streptococcus mutans/immunology | 2 | 50.0 |
Immunologic Deficiency Syndromes/*immunology | 2 | 5.0 |
B-Lymphocytes/cytology/drug effects/*immunology | 2 | 20.0 |
Interleukin-1/*physiology | 3 | 3.0 |
Lymphocytes/classification/*immunology | 4 | 21.0 |
Biological Factors/*pharmacology | 2 | 9.0 |
Thymus Gland/*cytology/immunology | 2 | 10.0 |
Cell Differentiation/*drug effects | 4 | 2.0 |
Antigens, Bacterial/*immunology | 2 | 1.0 |
Growth Substances/*metabolism | 2 | 1.0 |
Monocytes/*metabolism | 2 | 0.0 |
Antibodies, Anti-Idiotypic/immunology | 2 | 5.0 |
Ethers/pharmacology | 4 | 21.0 |
Receptors, Antigen, T-Cell, gamma-delta | 2 | 3.0 |
Killer Cells/*physiology | 2 | 33.0 |
Suppressor Factors, Immunologic/*pharmacology | 2 | 50.0 |
Lymphokines/*genetics | 3 | 1.0 |
Antigens, Surface/*immunology | 4 | 2.0 |
Calcium/physiology | 5 | 2.0 |
Half-Life | 3 | 0.0 |
Receptors, Immunologic/*metabolism | 4 | 2.0 |
Receptors, Interleukin-2 | 55 | 48.0 |
Colony-Stimulating Factors/analysis | 2 | 40.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Leukocytes, Mononuclear/physiology | 2 | 6.0 |
*Hematopoiesis | 2 | 1.0 |
Acquired Immunodeficiency Syndrome/immunology | 2 | 2.0 |
Antigens, Viral/analysis | 2 | 2.0 |
Viral Envelope Proteins/*immunology | 2 | 5.0 |
Neoplasms/*pathology | 2 | 3.0 |
Lymphocytes/*physiology | 3 | 3.0 |
Antibodies, Monoclonal/physiology | 6 | 8.0 |
Antigens, CD27 | 12 | 28.0 |
Antigens, Surface/immunology | 10 | 5.0 |
Growth Substances/biosynthesis | 3 | 15.0 |
Hematopoietic Cell Growth Factors | 2 | 16.0 |
Transforming Growth Factors | 2 | 2.0 |
Recombinant Proteins/*pharmacology | 4 | 4.0 |
Leukemia, Lymphocytic/*immunology | 4 | 13.0 |
Antibodies, Monoclonal/*physiology | 6 | 15.0 |
T-Lymphocytes/classification | 2 | 6.0 |
Calmodulin/antagonists & inhibitors | 2 | 10.0 |
Tonsil/cytology | 6 | 7.0 |
Immunoglobulins/secretion | 2 | 25.0 |
Interleukin-2/*biosynthesis/physiology | 3 | 100.0 |
Immunologic Deficiency Syndromes/immunology | 2 | 11.0 |
Interleukins/analysis | 2 | 6.0 |
Lymphokines/*metabolism | 2 | 0.0 |
T-Lymphocytes/*drug effects/metabolism | 2 | 5.0 |
T-Lymphocytes/immunology/microbiology | 2 | 18.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Histocompatibility Antigens Class II/*immunology | 2 | 1.0 |
Rats, Inbred Strains | 3 | 0.0 |
Antigens, Surface/analysis/immunology | 2 | 12.0 |
Dinoprostone | 6 | 8.0 |
Lymphocytes/classification | 2 | 6.0 |
Concanavalin A/*pharmacology | 4 | 14.0 |
Lymphokines/isolation & purification/*physiology | 2 | 50.0 |
Epitopes/*analysis | 2 | 1.0 |
Prostaglandins E/biosynthesis | 3 | 13.0 |
Cell Division/*drug effects | 2 | 0.0 |
DNA Replication | 6 | 1.0 |
Receptors, Immunologic/*immunology | 3 | 2.0 |
Stem Cells/*pathology | 2 | 12.0 |
Interleukin-2 | 4 | 23.0 |
Receptors, Immunologic/biosynthesis | 4 | 13.0 |
Antibodies/immunology | 2 | 0.0 |
Homosexuality | 3 | 2.0 |
Histocompatibility Antigens Class II/immunology | 4 | 2.0 |
B-Lymphocytes/classification/*immunology | 2 | 22.0 |
*Cell Transformation, Viral | 7 | 4.0 |
Immunity, Natural | 3 | 1.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
Lymphocytes/drug effects/metabolism | 2 | 6.0 |
Binding Sites, Antibody | 2 | 0.0 |
*Lymphocyte Cooperation | 2 | 7.0 |
Receptors, Transferrin | 3 | 15.0 |
Recombinant Proteins/physiology | 3 | 33.0 |
Herpesvirus 4, Human | 3 | 2.0 |
Phorbols/*pharmacology | 4 | 11.0 |
*Cloning, Molecular | 3 | 0.0 |
DNA/isolation & purification | 2 | 1.0 |
*Genes, Structural | 3 | 0.0 |
Immune Adherence Reaction | 3 | 6.0 |
Lectins/*pharmacology | 2 | 5.0 |
HLA Antigens/genetics | 2 | 0.0 |
Mice, Inbred DBA | 2 | 0.0 |
Clone Cells/classification/immunology | 2 | 28.0 |
Histocompatibility Antigens Class II | 3 | 6.0 |
*Antibody Formation | 2 | 2.0 |
Bacteriophage lambda/genetics | 2 | 4.0 |
Interleukin-2/*biosynthesis/isolation & purification | 2 | 100.0 |
Graft vs Host Disease/immunology | 2 | 6.0 |
*Chromosomes, Human, 4-5 | 2 | 12.0 |
Leucine/*analogs & derivatives/pharmacology | 2 | 16.0 |
Receptors, Immunologic/drug effects | 2 | 25.0 |
Adsorption | 2 | 1.0 |
Growth Substances/*isolation & purification | 2 | 18.0 |
Interferon Type II/*isolation & purification | 2 | 66.0 |
Interleukin-2/*isolation & purification | 2 | 66.0 |
Isoelectric Focusing | 3 | 0.0 |
Lymphokines/*isolation & purification | 2 | 22.0 |
Sepharose/analogs & derivatives | 2 | 10.0 |
Silicic Acid | 2 | 100.0 |
DNA Restriction Enzymes | 2 | 0.0 |
Neuraminidase/pharmacology | 2 | 2.0 |
Interleukin-1 | 2 | 16.0 |
Antigens, CD95/immunology | 2 | 3.0 |
